Skip to main content
Premium Trial:

Request an Annual Quote

Genentech: Aviv Regev

Aviv Regev will join Genentech as head of research and early development, effective August 1. She will replace Michael Varney, who will retire from his post at the end of July, and will also join Genentech's enlarged corporate executive committee. Regev is currently faculty chair, core institute member, and a member of the executive leadership team at the Broad Institute, as well as a professor of biology at the Massachusetts Institute of Technology and a Howard Hughes Medical Institute investigator. Prior to that, she was a Bauer fellow at the Center for Genomics Research at Harvard University. Regev holds a PhD in computational biology and a master of science degree from Tel Aviv University.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.